License and Patent Agreements - Additional Information (Detail)	12 Months Ended	1 Months Ended		12 Months Ended					1 Months Ended				12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014 Biolipox AB [Member] USD ($)	Aug. 31, 2009 Biolipox AB [Member] CAD	Dec. 31, 2014 Biolipox AB [Member] USD ($)	Dec. 31, 2013 Aquinox Pharmaceuticals (Canada) Inc. [Member] USD ($)	Dec. 31, 2012 Aquinox Pharmaceuticals (Canada) Inc. [Member] USD ($)	Dec. 31, 2014 SHIP1 Product Candidates [Member] CAD	Dec. 31, 2013 SHIP1 Product Candidates [Member] CAD	Jun. 30, 2006 SHIP1 Product Candidates [Member] First Drug Product [Member] CAD	Jun. 30, 2006 SHIP1 Product Candidates [Member] Subsequent Drug Product [Member] CAD	Jun. 30, 2006 SHIP1 Product Candidates [Member] Aquinox Pharmaceuticals (Canada) Inc. [Member] CAD	May 31, 2005 SHIP1 Enzyme and Screening of Product Candidates [Member] CAD	Dec. 31, 2014 SHIP1 Enzyme and Screening of Product Candidates [Member] CAD	Dec. 31, 2013 SHIP1 Enzyme and Screening of Product Candidates [Member] CAD	Dec. 31, 2012 SHIP1 Enzyme and Screening of Product Candidates [Member] CAD
Patent Licenses [Line Items]
Patent rights description	The agreement expires at the earlier of the last expiry of any patent obtained related to the technology or through enactment of one of the termination clauses stipulated in the agreement.
Amount of initial license fee			50,000								50,000	150,000
Common shares issued for license fee											100,000
Amount of development milestones payment			3,000,000						2,200,000	1,500,000
License agreement, maintenance fees							1,000	1,000					5,000	5,000	5,000
License agreement expiration period												20 years
Amount of annual maintenance fees												5,000
Value of exchangeable shares issued for license fee			250,000
Receipt of regulatory approval milestone payment			1,500,000
Royalty payments				0
Number of common stock issued for payment for achievement of milestone		19,762
Fair value of shares issued		186,356
Amount of expense for asset purchase agreement					$ 0	$ 0